文献速递慢性静脉疾病

静脉腔内激光消融联合或不联合切除术治疗静脉曲张的回顾性分析

Endovenous Laser Ablation with and Without Concomitant Phlebectomy for the Treatment of Varicose Veins: A Retrospective Analysis of 954 Limbs.
PubMed 文献 · Ann Vasc Surg · 2020-01-07

本研究回顾性分析了954条肢体接受静脉腔内激光消融(EVLA)联合或不联合同期静脉切除术的病例,比较随访期间需额外硬化治疗的比例。结果显示两组额外硬化治疗率无统计学差异,女性是额外硬化治疗的显著预测因素,支持在初次EVLA时避免同期静脉切除术的策略。

要点

  • EVLA联合或不联合同期静脉切除术,随访期间额外硬化治疗率无显著差异。
  • 女性与额外硬化治疗显著相关(OR 6.18,95%CI 1.86-20.6,P=0.003)。
  • 同期静脉切除术并非额外硬化治疗的显著预测因素(OR 0.844,95%CI 0.375-1.90,P=0.682)。

核心结论

  • 患者对额外硬化治疗的偏好在接受EVLA联合或不联合同期静脉切除术的两组间相当。
  • 结果支持在初次EVLA时避免同期静脉切除术的现行策略。

研究设计与样本

  • 数据前瞻性收集并补充回顾性病历审查,比较EVLA联合或不联合同期静脉切除术的结局。

主要发现

  • 随访期间,954条肢体中有34条(3.6%)因EVLA后残留可见静脉曲张接受额外硬化治疗。
  • 两组额外硬化治疗率无统计学差异(P=0.849)。
  • 非静脉切除术组EVLA后疼痛显著多于静脉切除术组(P=0.005)。

关键数值与推荐

  • CEAP分级、手术时间、激光设备类型、治疗静脉长度、线性静脉内能量密度和肿胀局部麻醉体积在两组间差异显著(均P<0.001)。
  • 女性与额外硬化治疗显著相关(OR 6.18;95%CI 1.86-20.6;P=0.003)。
  • 同期静脉切除术不是额外硬化治疗的显著预测因素(OR 0.844;95%CI 0.375-1.90;P=0.682)。

临床怎么用

  • 对于有症状的原发性静脉曲张患者,EVLA时可考虑避免同期静脉切除术,以减少手术创伤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovenous laser ablation (EVLA) with concomitant phlebectomy is commonly performed in many institutions. However, phlebectomy is associated with cosmetic complications such as surgical scarring, hemorrhage, and hematoma. This study aims to compare the need for additional sclerotherapy during follow-up after EVLA with and without concomitant phlebectomy. METHODS: Between November 2013 and December 2018, we performed EVLA on 1,363 limbs in 1,009 patients with symptomatic primary varicose veins, of which 954 limbs in 771 patients with great saphenous vein (GSV) or small saphenous vein (SSV) insufficiency were included in this study. Data were collected prospectively and supplemented with retrospective medical record review. Demographic and clinical characteristic profiles were collected. The outcomes of EVLA with or without concomitant phlebectomy were compared. Logistic regression was used to assess predictors for additional sclerotherapy after EVLA. RESULTS: CEAP classification (P < 0.001), operative time (P < 0.001), laser device type (P < 0.001), length of the treated vein (P < 0.001), linear endovenous energy density (P < 0.001), and tumescent local anesthesia volume (P < 0.001) differed significantly. Pain after EVLA was significantly more frequent in the nonphlebectomy group than in the phlebectomy group (P = 0.005). During follow-up, 34 of 954 limbs (3.6%) underwent additional sclerotherapy for residual visible varicose veins after EVLA. No statistical difference was found in the rate of additional sclerotherapy between the groups (P = 0.849). Logistic regression showed that female sex (odds ratio [OR], 6.18; 95% confidence interval [CI], 1.86-20.6; P = 0.003) is significantly associated with additional sclerotherapy, and concomitant phlebectomy is not a significant predictor of additional sclerotherapy (OR, 0.844; 95% CI, 0.375-1.90; P = 0.682). CONCLUSIONS: Patient preference for additional sclerotherapy was comparable between those who underwent EVLA with and without concomitant phlebectomy. This result supports our present strategy of avoiding simultaneous phlebectomy at the time of primary EVLA.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Kawai Y, Sugimoto M, Aikawa K, et al. Endovenous Laser Ablation with and Without Concomitant Phlebectomy for the Treatment of Varicose Veins: A Retrospective Analysis of 954 Limbs. Ann Vasc Surg. 2020. PMID: 31917221. doi:10.1016/j.avsg.2019.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。